The Latest
-
Making the leap from the lab to the boardroom
Four academics-turned-executives share what they’ve learned about the pivot point between life sciences academia and entrepreneurship.
-
‘The Last of Us’ might be fiction, but fungi are a looming threat
Fungal infections are a growing challenge for hospitalized patients, and new treatments are badly needed.
-
Biotech Spotlight
This biotech’s ‘Microsoft’ approach could change how we see gene therapy
The company’s using a unique component-based platform to develop functional cures for diseases, including HIV.
-
A biopharma CEO’s quest for global health equity has put him in the running for a Nobel Prize
Dr. Ryan Saadi, CEO of Tevogen Bio, is making good on a lifelong goal of bringing T cell therapies to people who need them.
-
Return of the megadeal: Pfizer’s Seagen buy has the industry asking if super-sized M&A is back
A $43 billion deal that doubles the pharma giant's cancer pipeline shows that M&A is back on the table in pharma.
-
Making Moves
In the fallout from Aduhelm, Biogen’s leadership shakeup continues
The recent departure of neurodegenerative development head Samantha Budd Haeberlein is just the latest sign of a changing tide among Biogen’s post-Aduhelm leadership.
-
PharmaVoice 100
The PharmaVoice 100 — Who makes the cut
What we’re looking for in each new class of honorees.
-
Podcast
Woman of the Week: Novartis Gene Therapies’ Chris Fox
Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. When Novartis acquired AveXis and its spinal muscular atroph...
-
Profile
A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch
To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.
-
Profile
The power of connections for a startup CEO
Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.
-
Biden doubles down on drug pricing in 2024 budget — but boosts R&D
The president’s 2024 budget proposal expands on last year’s drug pricing reforms, but also dramatically increases innovation investments.
-
Q&A
Babson aims to shed Theranos curse with new blood testing tech
Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?
-
Q&A
IQVIA’s OG of data analytics on the latest clinical trial trends
IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.
-
Q&A // Biotech Spotlight
While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer
The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.
-
Janssen neuroscience leader takes on rare diseases one small ‘eureka’ at a time
Fueled by a fascination with the scientific process, Sindhu Ramchandren is exploring how a new drug could treat patients with a range of rare diseases.
-
Targeting the new ‘Golden Girls’
With unprecedented buying power, women over 50 wield a lot of influence — but are still underserved by pharma. Urovant hopes to change that with its potential blockbuster drug.
-
Podcast
Woman of the Week: Lucy Therapeutics’ Amy Ripka
How a 3.2-million-year-old fossil inspired the CEO to unlock the mysteries of mitochondrial dysfunction.
-
Eli Lilly took price cuts into its own hands. Will other pharmas follow suit?
The pharma giant took the high road and cut prices before the feds made them. How will that affect the industry?
-
3 keys to good storytelling in pharma
The CEO of Complement Therapeutics shares simple storytelling tactics lead to maximum impact.
-
Why layoffs are not the answer to biopharma’s troubled market
As companies look to cut costs, an EY analyst urges them to consider not cutting staff.
-
FDA ups generics and biosimilar approvals for a shot at lower drug costs
As the Biden administration searched for drug-cost reducing measures, the FDA incentivized generic and biosimilar development in 2022.
-
PharmaVoice 100 honorees: Where are they now?
How some of our past PharmaVoice 100 honorees are transforming the life sciences industry in new roles.
-
Q&A // First 90 Days
The ‘recovering academic’ leading Allogene to the next stage of cell therapy
Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.
-
Q&A // Biotech Spotlight
Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology
With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.
-
Do R&D costs justify the price of drugs? Nope, new study says
A BMJ study found that spending on drug sales vastly outstripped spending on drug development.